| Identification | Back Directory | [Name]
ABT-639 | [CAS]
1235560-28-7 | [Synonyms]
ABT-639
4-Chloro-2-fluoro-N-(2-fluorophenyl)-5-[[(8aR)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl]carbonyl]benzenesulfonamide | [Molecular Formula]
C20H20ClF2N3O3S | [MDL Number]
MFCD29924737 | [MOL File]
1235560-28-7.mol | [Molecular Weight]
455.91 |
| Chemical Properties | Back Directory | [Boiling point ]
612.2±65.0 °C(Predicted) | [density ]
1.51±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO:9.71(Max Conc. mg/mL);21.3(Max Conc. mM)
DMF:14.0(Max Conc. mg/mL);30.71(Max Conc. mM)
DMF:PBS (pH 7.2) (1:20):0.04(Max Conc. mg/mL);0.09(Max Conc. mM)
Ethanol:0.5(Max Conc. mg/mL);1.1(Max Conc. mM) | [form ]
A solid | [pka]
6.80±0.10(Predicted) |
| Questions and Answers (Q&A) | Back Directory | [Description]
ABT-639 is a selective T-type calcium channel blocker with efficacy in a wide range of preclinical models of nociceptive and neuropathic pain.ABT-639 produces robust antinociceptive activity in experimental pain models at doses that do not significantly alter psychomotor or hemodynamic function in the rat.
| [References]
Zhang, Q., et al. "Optimization of ADME Properties for Sulfonamides Leading to the Discovery of a T-Type Calcium Channel Blocker, ABT-639."Acs Medicinal Chemistry Letters6.6(2015):150429091057009.
Serra, J, et al. "Effects of a T-type calcium channel blocker, ABT-639, on spontaneous activity in C-nociceptors in patients with painful diabetic neuropathy: a randomized controlled trial. " Pain 156.11(2015):2175.
http://www.medkoo.com/products/6989
|
|
|